Aktis Oncology (NASDAQ:AKTS) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $30.00 price objective on the technology company’s stock.

A number of other equities research analysts also recently commented on the stock. Bank of America began coverage on shares of Aktis Oncology in a research report on Tuesday. They issued a “buy” rating and a $34.00 target price for the company. Leerink Partners assumed coverage on Aktis Oncology in a report on Tuesday. They issued an “outperform” rating and a $31.00 price objective for the company. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Finally, TD Cowen initiated coverage on Aktis Oncology in a research report on Tuesday. They issued a “buy” rating on the stock. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $31.67.

Aktis Oncology Price Performance

Shares of NASDAQ AKTS opened at $19.57 on Tuesday. Aktis Oncology has a 52-week low of $18.02 and a 52-week high of $29.16.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc purchased 2,222,222 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the completion of the transaction, the director directly owned 4,348,658 shares in the company, valued at $78,275,844. This represents a 104.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Helen Susan Kim acquired 835,000 shares of the stock in a transaction dated Monday, January 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the director owned 5,671,825 shares in the company, valued at approximately $102,092,850. This represents a 17.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 6,117,776 shares of company stock worth $110,119,968 in the last quarter. Company insiders own 3.30% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.